Receptor Test (Pupillary Dilatation after Application of 0.01% Tropicamide Solution) and Determination of Central Nervous Activation (Fourier Analysis of Pupillary Oscillations) in Patients with Alzheimer’s Disease

1999 ◽  
Vol 40 (1) ◽  
pp. 40-46 ◽  
Author(s):  
J. Grünberger ◽  
L. Linzmayer ◽  
H. Walter ◽  
M. Rainer ◽  
A. Masching ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Fourier Analysis ◽  
Pupillary Dilatation ◽  
Pupillary Oscillations ◽  
Central Nervous Activation

A ratiometric electrochemical strategy for sensitive determination of Furin activity based on dual signal amplification and antifouling nanosurfaces

The Analyst ◽  
2017 ◽  
Vol 142 (22) ◽  
pp. 4215-4220 ◽  
Author(s):  
Dazhi Yao ◽  
Wenqi Zhao ◽  
Limin Zhang ◽  
Yang Tian
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cell Surface ◽  
Signal Amplification ◽  
Accurate Method ◽  
Sensitive Determination ◽  
Dual Signal Amplification

Developing a sensitive and accurate method for Furin activity is still the bottleneck for understanding the role played by Furin in cell-surface systems and even in Alzheimer's disease.

Automatic determination of white matter hyperintensity properties in relation to the development of Alzheimer's disease

2016 ◽  
Author(s):  
Sandra van der Velden ◽  
Christoph Moenninghoff ◽  
Isabel Wanke ◽  
Martha Jokisch ◽  
Christian Weimar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
White Matter ◽  
White Matter Hyperintensity ◽  
Automatic Determination

UPLC-MS/MS method for determination of schisandrin in rat plasma and brain microdialysates: application to a comparative pharmacokinetic and brain distribution study in normal and Alzheimer’s disease rats

2017 ◽  
Vol 9 (32) ◽  
pp. 4740-4746 ◽  
Author(s):  
BinBin Wei ◽  
Mingyan Liu ◽  
Zaixing Chen ◽  
Minjie Wei
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Rat Plasma ◽  
Brain Distribution ◽  
Comparative Pharmacokinetic ◽  
Distribution Study

An efficient UPLC-MS/MS method for determining schisandrin in rat plasma and brain microdialysates has been developed and validated.

A peptide–WS2 nanosheet based biosensing platform for determination of β-secretase and screening of its inhibitors

The Analyst ◽  
2018 ◽  
Vol 143 (19) ◽  
pp. 4585-4591 ◽  
Author(s):  
Xianwei Zuo ◽  
Hongxia Dai ◽  
Huige Zhang ◽  
Juanjuan Liu ◽  
Sudai Ma ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Drug Target ◽  
Important Drug

β-Secretase (BACE1) is an important drug target in the treatment of Alzheimer's disease (AD).

Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease

2014 ◽  
Vol 28 (11) ◽  
pp. 1431-1490 ◽  
Author(s):  
Suresh Ponnayyan Sulochana ◽  
Kuldeep Sharma ◽  
Ramesh Mullangi ◽  
Sathesh Kumar Sukumaran
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Practice

scholarly journals Commentary

1998 ◽  
Vol 4 (6) ◽  
pp. 364-366 ◽  
Author(s):  
D. Neill
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Lewy Bodies ◽  
Neuronal Loss ◽  
Pathological Process ◽  
Psychotic Symptoms ◽  
Extrapyramidal Features ◽  
Relationship Of ◽  
The Relationship

The article by Byrne gives a general overview of dementia with Lewy bodies (LBD) and discusses treatment in terms of modulation of neurotransmitter systems, treatment of psychotic symptoms and extrapyramidal features. However, as is the case with Alzheimer's disease, the dementia is related to underlying pathological processes which result in death and/or malfunction of neurons. Prevention or amelioration of this neuronal loss is therefore the ultimate aim of treatment. Such treatment is not yet available and the possibility of its development is likely to depend on further elucidation of the underlying pathological process. The relationship of LBD to Alzheimer's disease and Parkinson's disease should be considered, as this is important for the determination of the underlying pathological processes in LBD.

Proteomic determination of widespread detergent insolubility, including Aβ but not tau, early in the pathogenesis of Alzheimer's disease

2005 ◽  
Vol 19 (13) ◽  
pp. 1923-1925 ◽  
Author(s):  
Randall L. Woltjer ◽  
P. J. Cimino ◽  
Angela M. Boutté ◽  
Aimee M. Schantz ◽  
Kathleen S. Montine ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease
Sign in / Sign up

Export Citation Format

Share Document